Summary
Market Context
Top Queries
More News
Related Stories
Suraksha Diagnostic Q3 FY26 Earnings Call: Investor Presentation Out
Suraksha Diagnostic Limited
February 5, 2026, 03:08 PM
Suraksha Diagnostic Limited released its investor presentation for Q3 & 9M FY26. The company reported a 30% YoY revenue increase in Q3 FY26 to ₹783 million, driven by expansion. EBITDA grew 26% to ₹238 million. Key initiatives include the launch of Suraksha Genomics and the acquisition of Fetomat Wellness.
Top Queries to Ask About Suraksha Diagnostic Limited
InstantThinking to buy or sell Suraksha Diagnostic Limited? Ask AI before you act.
Trusted by 5,000+ users
More Details on This News
Suraksha Diagnostic Limited has announced its investor presentation for the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. The presentation will be showcased during the Earnings Call scheduled for Friday, February 06, 2026, at 2:30 PM IST. The company has also provided a management commentary highlighting a strong financial performance with revenue rising 30% year-on-year for the quarter, driven by an aggressive expansion plan. While EBITDA saw a planned marginal compression due to pre-operative expenses of new centers, the core business demonstrated a robust 37% EBITDA. The launch of the 'Suraksha Sutra' Genomics/Molecular vertical has received positive market reception, establishing a significant first-mover advantage in Eastern India. The company stated its strategy as "Investing for Scale: Short-term Compression for Long-term Dominance" to deliver solid long-term shareholder value.
Key financial highlights for Q3 FY26 include a 30% year-on-year increase in Total Income to ₹783 million, EBITDA growth of 26% to ₹238 million, and a 21% increase in PAT to ₹72 million. For the nine months ended December 31, 2025, Total Income grew by 22% to ₹2,314 million, EBITDA by 13% to ₹734 million, and PAT by 6% to ₹252 million. Operating metrics for 9M FY26 show Revenue per Patient at ₹2,140, EBITDA per Patient at ₹686, and 6.18 million tests performed, serving 1.07 million patients across 66 diagnostic centers.
The company also detailed its strategic expansion, including the acquisition of a 63% stake in Fetomat Wellness Private Limited in April 2025, a network of fertility and pregnancy care clinics. The launch of Suraksha Genomics in July 2025, a new vertical for advanced genetic and molecular testing services, is positioned as a key growth lever. Expansion plans include opening additional centers in Q4 FY26 and consolidating its leading position in Eastern and North-Eastern India through organic and inorganic routes. The company emphasizes its 'hub and spoke' operating model and its focus on leveraging technology to enhance customer experience.
More News on Suraksha Diagnostic Limited
Analyze Suraksha Diagnostic Limited